$ATYR
aTyr Pharma Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023019686 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.720M $3.408M $3.482M
YoY Change 7.86% -2.13% 29.44%
% of Gross Profit
Research & Development $9.840M $9.379M $8.896M
YoY Change 7.72% 5.43% 96.81%
% of Gross Profit
Depreciation & Amortization $161.0K $80.00K $81.00K
YoY Change 155.56% -1.23% -33.06%
% of Gross Profit
Operating Expenses $13.56M $12.79M $8.896M
YoY Change 7.74% 43.74% 23.56%
Operating Profit -$13.56M -$12.79M -$12.38M
YoY Change 7.74% 3.3%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.216M $835.0K $224.0K
YoY Change 646.01% 272.77% 376.6%
Pretax Income -$12.34M -$11.95M -$12.15M
YoY Change -0.65% -1.66% 69.75%
Income Tax
% Of Pretax Income
Net Earnings -$12.30M -$12.00M -$12.20M
YoY Change -0.81% -1.64% 70.51%
Net Earnings / Revenue
Basic Earnings Per Share -$0.22 -$0.29 -$0.44
Diluted Earnings Per Share -$0.22 -$0.29 -$436.9K
COMMON SHARES
Basic Shares Outstanding 54.29M 53.16M 27.80M
Diluted Shares Outstanding 55.14M 41.90M 27.82M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.6M $114.4M $98.67M
YoY Change 22.62% 15.93% 94.85%
Cash & Equivalents $12.31M $20.69M $8.324M
Short-Term Investments $96.27M $93.70M $90.34M
Other Short-Term Assets $4.563M $3.437M $4.025M
YoY Change 4.3% -14.61% 187.5%
Inventory
Prepaid Expenses $4.563M $3.437M
Receivables
Other Receivables $1.287M $1.625M
Total Short-Term Assets $114.4M $119.4M $103.1M
YoY Change 22.58% 15.84% 97.92%
LONG-TERM ASSETS
Property, Plant & Equipment $5.812M $5.167M $1.483M
YoY Change 941.58% 248.42% -47.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $72.00K $144.0K $176.0K
YoY Change -58.86% -18.18% -24.79%
Total Long-Term Assets $18.32M $17.39M $1.659M
YoY Change 588.31% 948.28% -45.21%
TOTAL ASSETS
Total Short-Term Assets $114.4M $119.4M $103.1M
Total Long-Term Assets $18.32M $17.39M $1.659M
Total Assets $132.7M $136.8M $104.8M
YoY Change 38.26% 30.6% 90.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $516.0K $3.965M $1.563M
YoY Change -69.18% 153.68% 34.63%
Accrued Expenses $10.79M $8.888M $4.706M
YoY Change 63.21% 88.87% 96.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $443.0K $420.0K
YoY Change 532.86%
Total Short-Term Liabilities $12.37M $13.65M $6.269M
YoY Change 33.56% 117.8% 39.31%
LONG-TERM LIABILITIES
Long-Term Debt $1.525M $1.570M $0.00
YoY Change 411.74%
Other Long-Term Liabilities $12.80M $11.92M $133.0K
YoY Change 8859.4% -87.91%
Total Long-Term Liabilities $14.33M $13.49M $133.0K
YoY Change 4707.72% 10039.85% -87.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.37M $13.65M $6.269M
Total Long-Term Liabilities $14.33M $13.49M $133.0K
Total Liabilities $26.51M $26.96M $6.226M
YoY Change 182.59% 333.01% 15.3%
SHAREHOLDERS EQUITY
Retained Earnings -$441.9M -$429.6M -$384.4M
YoY Change 11.34% 11.76% 11.2%
Common Stock $57.00K $53.00K
YoY Change 103.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.2M $109.9M $98.55M
YoY Change
Total Liabilities & Shareholders Equity $132.7M $136.8M $104.8M
YoY Change 38.26% 30.6% 90.06%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$12.30M -$12.00M -$12.20M
YoY Change -0.81% -1.64% 70.51%
Depreciation, Depletion And Amortization $161.0K $80.00K $81.00K
YoY Change 155.56% -1.23% -33.06%
Cash From Operating Activities -$12.01M -$590.0K -$10.12M
YoY Change 31.73% -94.17% 73.66%
INVESTING ACTIVITIES
Capital Expenditures $2.395M $1.246M -$43.00K
YoY Change -4618.87% -2997.67% -352.94%
Acquisitions
YoY Change
Other Investing Activities -$1.761M -$36.93M $14.67M
YoY Change -117.57% -351.73% -162.74%
Cash From Investing Activities -$4.156M -$38.17M $14.63M
YoY Change -141.68% -360.99% -162.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.018M 49.50M 1.481M
YoY Change 20458.97% 3242.07% -94.04%
NET CHANGE
Cash From Operating Activities -12.01M -590.0K -10.12M
Cash From Investing Activities -4.156M -38.17M 14.63M
Cash From Financing Activities 8.018M 49.50M 1.481M
Net Change In Cash -8.148M 10.73M 5.988M
YoY Change -1012.43% 79.26% -237.18%
FREE CASH FLOW
Cash From Operating Activities -$12.01M -$590.0K -$10.12M
Capital Expenditures $2.395M $1.246M -$43.00K
Free Cash Flow -$14.41M -$1.836M -$10.08M
YoY Change 58.93% -81.78% 72.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001339970
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37378
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3435077
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
10240 Sorrento Valley
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2023Q1 dei City Area Code
CityAreaCode
858
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
731-8389
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
LIFE
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54291754
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20690000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9981000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
93695000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
56165000
CY2023Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1625000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
11775000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3437000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2950000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
539659000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
489502000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-248000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
119447000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
80871000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3190000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3165000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5167000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3059000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6942000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7250000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1948000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1248000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2023Q1 us-gaap Assets
Assets
136838000
CY2022Q4 us-gaap Assets
Assets
95786000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3965000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3106000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8888000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9862000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
381000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
630000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
420000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
264000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
13654000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13862000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11916000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9633000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1570000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1007000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53339611
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53339611
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29498488
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29498488
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
53000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-433000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-429585000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-417634000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
109879000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
71464000
CY2023Q1 us-gaap Minority Interest
MinorityInterest
-181000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-180000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109698000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71284000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136838000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95786000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9379000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8896000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3408000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3482000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
12787000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
12378000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12787000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12378000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
835000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
224000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11952000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11951000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-12153000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41897706
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41897706
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27818379
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27818379
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11952000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
185000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-496000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11767000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12650000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11766000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12649000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71284000
CY2023Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1489000
CY2023Q1 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
48073000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
619000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
185000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11952000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109698000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1480000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-496000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98374000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11952000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
80000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
81000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
619000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
417000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
419000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-237000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
675000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
217000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
89000
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9883000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
438000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1180000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1057000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
216000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2019000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-233000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-590000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10119000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1246000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
46226000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
9300000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
14500000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
169000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38172000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14626000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1000
CY2023Q1 life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
1489000
CY2022Q1 life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
1480000
CY2023Q1 life Proceeds From Issuance Of Common Stock Through Underwritten Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenPublicOfferingNetOfOfferingCosts
48073000
CY2022Q1 life Proceeds From Issuance Of Common Stock Through Underwritten Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenPublicOfferingNetOfOfferingCosts
0
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
66000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49496000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1481000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10734000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5988000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13146000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2336000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23880000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8324000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20690000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8324000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3190000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23880000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8324000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
46000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023Q1 life Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
2136000
CY2022Q1 life Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1043000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-12000000.0
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-429600000
CY2023Q1 life Cash And Cash Equivalents Restricted Cash And Available For Sale Investments
CashAndCashEquivalentsRestrictedCashAndAvailableForSaleInvestments
117600000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3200000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to clinical trial and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</span></p>
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3971278
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1839969
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
93893000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
42000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
240000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
93695000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56548000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
383000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
56165000
CY2023Q1 life Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
200000
CY2022Q4 life Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
200000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
23696
CY2023Q1 life Lessee Operating Lease Lease Commencement Date
LesseeOperatingLeaseLeaseCommencementDate
2023-03-20
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
CY2023Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
We have an option to extend the Lease Term for five years.
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2022Q2 life Base Rent Per Square Foot
BaseRentPerSquareFoot
5.75
CY2022Q2 life Annual Upward Adjustments On Base Rate Percentage
AnnualUpwardAdjustmentsOnBaseRatePercentage
0.030
CY2023Q1 us-gaap Tenant Improvements
TenantImprovements
5500000
CY2023Q1 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
4500000
CY2022Q2 life Additional Allowance For Tenant Improvements
AdditionalAllowanceForTenantImprovements
600000
CY2022Q2 life Base Rent Amortized Percentage
BaseRentAmortizedPercentage
0.080
CY2023Q1 us-gaap Security Deposit
SecurityDeposit
700000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1031000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1976000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1909000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1777000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1831000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
11103000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6680000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
12947000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
381000
CY2023Q1 life Lessee Operating Lease Liability Tenant Improvement Allowance Not Yet Received
LesseeOperatingLeaseLiabilityTenantImprovementAllowanceNotYetReceived
650000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11916000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2023Q1 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P48M
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
422000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
563000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
563000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
606000
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
185000
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
349000
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
1990000
CY2023Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
420000
CY2023Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1570000
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.082
CY2022Q2 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.030
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4931157
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2956170
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.45
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
938485
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.20
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
71052
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.37
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3823603
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.22
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
619000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
417000

Files In Submission

Name View Source Status
life-20230331_cal.xml Edgar Link unprocessable
0000950170-23-019686-index-headers.html Edgar Link pending
0000950170-23-019686-index.html Edgar Link pending
0000950170-23-019686.txt Edgar Link pending
0000950170-23-019686-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
life-20230331.htm Edgar Link pending
life-20230331.xsd Edgar Link pending
life-ex31_1.htm Edgar Link pending
life-ex31_2.htm Edgar Link pending
life-ex32_1.htm Edgar Link pending
life-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
life-20230331_pre.xml Edgar Link unprocessable
life-20230331_def.xml Edgar Link unprocessable
life-20230331_lab.xml Edgar Link unprocessable
life-20230331_htm.xml Edgar Link completed